Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272937 | 1.00 | SYK (0.58) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL3272940 | 1.00 | SYK (0.58) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL7497038 | 0.90 | SYK (0.61) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL3276799 | 0.89 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL14119009 | 0.89 | ATM (0.62) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL17207697 | 0.89 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL3108565 | 0.89 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL15928906 | 0.89 | ATM (0.62) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL6685926 | 0.89 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL1262680 | 0.89 | SYK (0.59) | SYKKLK5KLK7ATMPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| EP-1663966-B1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | LE GRAND DARREN M | 2007-02-22 | — | — | US | disclosed |
| EP-1663966-A1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005026113-A1 | 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | SYK 2729/4885KLK5 2931/4885KLK7 3967/4885 |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | CCR1, CCR3, CCR9 | SYK 1422/4885KLK5 2363/4885KLK7 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.